Covid-19 roundup: Top analyst: Regeneron EUA likely this week — unless Trump takes a turn for worse; UK says less than half of residents will be vaccinated
With Regeneron’s Covid-19 antibody cocktail being used to treat the highest-profile patient on the planet, one top analyst expects an EUA could be on the horizon.
SVB Leerink’s Geoffrey Porges sent a note to investors early Monday morning attempting to parse through what the use of REGN-CoV2 to alleviate President Donald Trump’s symptoms means for the company. Given that the therapy was used at all, Porges estimates that the FDA was already reviewing its EUA application and that the authorization could come “in a matter of days.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.